Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus PENTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus PENTAM.
ALINIA vs PENTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Pentamidine is an antiprotozoal agent that interferes with nucleotide and nucleic acid synthesis, possibly by binding to DNA and inhibiting RNA and protein synthesis. It also affects membrane integrity and inhibits oxidative phosphorylation.
500 mg orally twice daily for 3 days, with food.
4 mg/kg intravenously once daily for 21 days (Pneumocystis jirovecii pneumonia); or 300 mg deep intramuscularly every 3 weeks for prophylaxis.
None Documented
None Documented
Clinical Note
moderatePentamidine + Gatifloxacin
"Pentamidine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePentamidine + Rosoxacin
"Pentamidine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePentamidine + Trovafloxacin
"Pentamidine may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderatePentamidine + Nalidixic acid
"Pentamidine may increase the hypoglycemic activities of Nalidixic acid."
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
Terminal elimination half-life: 6-24 hours (prolonged in renal impairment; up to 48 hours in anuria).
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Renal: approximately 60-70% unchanged; biliary/fecal: minimal, <10%.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent